Restenosis: Delineating the numerous causes of drug-eluting stent restenosis

Circulation: Cardiovascular Interventions

Volumn 4, Issue 2, 2011, Pages 195-205

  Farooq, Vasim ^a   Gogas, Bill D ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Coronary stents; Drug eluting stents; In stent restenosis; Mechanisms; Percutaneous coronary intervention

Indexed keywords

EVEROLIMUS; MATRIX METALLOPROTEINASE; PACLITAXEL; POLYMER; RAPAMYCIN; GELATINASE A; GELATINASE B;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BARE METAL STENT; DRUG ELUTING STENT; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY REACTION; IN-STENT RESTENOSIS; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SHEAR STRESS; BLOOD; DRUG HYPERSENSITIVITY; SHEAR STRENGTH; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ATHEROSCLEROSIS; CORONARY RESTENOSIS; DRUG HYPERSENSITIVITY; DRUG-ELUTING STENTS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PACLITAXEL; SHEAR STRENGTH; SIROLIMUS;

EID: 80051759292     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.110.959882     Document Type: Review

References (68)

1. Duckers HJ, Nabel EG, Serruys PW, eds. Essentials of Restenosis: For the Interventional Cardiologist. Totowa, NJ: Humana Press; 2007.
2. Byrne RA, Eberle S, Kastrati A, Dibra A, Ndrepepa G, Iijima R, Mehilli J, Schomig A. Distribution of angiographic measures of restenosis after drug-eluting stent implantation. Heart. 2009;95:1572-1578.
3. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol. 2010;56:S1-S42.
4. Corbett SJ, Cosgrave J, Melzi G, Babic R, Biondi-Zoccai GG, Godino C, Morici N, Airoldi F, Michev I, Montorfano M, Sangiorgi GM, Bonizzoni E, Colombo A. Patterns of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus-and paclitaxel-eluting stents. Eur Heart J. 2006;27: 2330-2337. (Pubitemid 44453577)
5. van Beusekom HM, Saia F, Zindler JD, Lemos PA, Swager-Ten Hoor SL, van Leeuwen MA, de Feijter PJ, Serruys PW, van der Giessen WJ. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J. 2007;28:974-979. (Pubitemid 47343915)
6. Chieffo A, Foglieni C, Nodari RL, Briguori C, Sangiorgi G, Latib A, Montorfano M, Airoldi F, Michev I, Carlino M, Colombo A, Maseri A. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. Am J Cardiol. 2009;104:1660-1667.
7. Rathore S, Kinoshita Y, Terashima M, Katoh O, Matsuo H, Tanaka N, Kimura M, Tsuchikane E, Nasu K, Ehara M, Asakura K, Asakura Y, Suzuki T. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. EuroIntervention. 2010;5:841-846.
8. Steinberg DH, Pinto Slottow TL, Buch AN, Javaid A, Roy PK, Garg S, Okabe T, Torguson R, Smith KA, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Lindsay J, Waksman R. Impact of in-stent restenosis on death and myocardial infarction. Am J Cardiol. 2007;100:1109-1113. (Pubitemid 47404468)
9. Alfonso F. Treatment of drug-eluting stent restenosis the new pilgrimage: quo vadis? J Am Coll Cardiol. 2010;55:2717-2720.
10. Richardson A, Kaye SB. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance. Drug Resist Updat. 2005;8:311-321. (Pubitemid 41677714)
11. Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat. 2001;4:378-391. (Pubitemid 34746872)
12. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhofer D, Schuhlen H, Goos C, Pache J, Dotzer F, Pogatsa-Murray G, Dirschinger J, Heemann U, Schomig A. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation. 2004;110:790-795. (Pubitemid 39096005)
13. Nakazawa G, Finn AV, Ladich E, Ribichini F, Coleman L, Kolodgie FD, Virmani R. Drug-eluting stent safety: findings from preclinical studies. Expert Rev Cardiovasc Ther. 2008;6:1379-1391.
14. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ, Baim DS, Virmani R. Comparison of inflammatory response after implantation of sirolimus-and paclitaxel-eluting stents in porcine coronary arteries. Circulation. 2009;120:141-149; 1-2.
15. Cook S, Ladich E, Nakazawa G, Eshtehardi P, Neidhart M, Vogel R, Togni M, Wenaweser P, Billinger M, Seiler C, Gay S, Meier B, Pichler WJ, Juni P, Virmani R, Windecker S. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. 2009;120:391-399.
16. Patil SU, Long A. Nickel hypersensitivity and coronary artery stents. In: Basow DS, ed., UpToDate. Waltham, MA: UpToDate; 2010.
17. Nakazawa G, Tanabe K, Aoki J, Onuma Y, Higashikuni Y, Yamamoto H, Ohtsuki S, Yachi S, Yagishita A, Nakajima H, Hara K. Sirolimus-eluting stents suppress neointimal formation irrespective of metallic allergy. Circ J. 2008;72:893-896. (Pubitemid 351879908)
18. Katsaros KM, Kastl SP, Zorn G, Maurer G, Wojta J, Huber K, Christ G, Speidl WS. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and-9. J Am Coll Cardiol Cardiovasc Interv. 2010; 3:90-97.
19. Monraats PS, Pires NM, Agema WR, Zwinderman AH, Schepers A, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, Quax PH, van Vlijmen BJ, Atsma DE, van der Laarse A, van der Wall EE, Jukema JW. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation. 2005;112: 2417-2425. (Pubitemid 41504491)
20. Vogiatzi K, Apostolakis S, Voudris V, Thomopoulou S, Kochiadakis GE, Spandidos DA. Interleukin 8 gene polymorphisms and susceptibility to reste-nosis after percutaneous coronary intervention. J Thromb Thrombolysis. 2010;29:134-140.
21. Sterpetti AV, Cucina A, D'Angelo LS, Cardillo B, Cavallaro A. Shear stress modulates the proliferation rate, protein synthesis, and mitogenic activity of arterial smooth muscle cells. Surgery. 1993;113:691-699. (Pubitemid 23176314)
22. Wentzel JJ, Gijsen FJ, Schuurbiers JC, van der Steen AF, Serruys PW. The influence of shear stress on in-stent restenosis and thrombosis. EuroIntervention. 2008;4(suppl C):C27-C32.
23. Carlier SG, van Damme LCA, Blommerde CP, Wentzel JJ, van Langehove G, Verheye S, Kockx MM, Knaapen MWM, Cheng C, Gijsen F, Duncker DJ, Stergiopulos N, Slager CJ, Serruys PW, Krams R. Augmentation of wall shear stress inhibits neointimal hyperplasia after stent implantation: inhibition through reduction of inflammation? Circulation. 2003;107:2741-2746. (Pubitemid 36667250)
24. Kim YH, Park DW, Suh IW, Jang JS, Hwang ES, Jeong YH, Lee SW, Lee CW, Hong MK, Kim JJ, Park SW, Park SJ. Long-term outcome of simultaneous kissing stenting technique with sirolimus-eluting stent for large bifurcation coronary lesions. Catheter Cardiovasc Interv. 2007;70: 840-846.
25. Morton AC, Siotia A, Arnold ND, Korgul P, Bowles J, Heppenstall J, Gunn J. Simultaneous kissing stent technique to treat left main stem bifurcation disease. Catheter Cardiovasc Interv. 2007;69:209-215. (Pubitemid 46217722)
26. Stinis CT, Hu SP, Price MJ, Teirstein PS. Three-year outcome of drug-eluting stent implantation for coronary artery bifurcation lesions. Catheter Cardiovasc Interv. 2010;75:309-314.
27. Papafaklis MI, Bourantas CV, Theodorakis PE, Katsouras CS, Naka KK, Fotiadis DI, Michalis LK. The effect of shear stress on neointimal response following sirolimus-and paclitaxel-eluting stent implantation compared with bare-metal stents in humans. J Am Coll Cardiol Intv. 2010;3:1181-1189.
28. Ramcharitar S, Garcia-Garcia HM, Nakazawa G, Kukreja N, Ligthart J, Virmani R, Serruys PW. Ultrasonic and pathological evidence of a neo-intimal plaque rupture in patients with bare metal stents. EuroIntervention. 2007;3:290-291.
29. Hoole SP, Starovoytov A, Hamburger JN. In-stent restenotic lesions can rupture - A case against plaque sealing [Epub ahead of print September 17, 2010]. Catheter Cardiovasc Interv. doi: 10.1002/ccd.22791.
30. Waxman S, Freilich MI, Suter MJ, Shishkov M, Bilazarian S, Virmani R, Bouma BE, Tearney GJ. A case of lipid core plaque progression and rupture at the edge of a coronary stent: elucidating the mechanisms of drug-eluting stent failure. Circ Cardiovasc Interv. 2010;3:193-196.
31. Rodes-Cabau J, Bertrand OF, Larose E, Dery J-P, Rinfret S, Bagur R, Proulx G, Nguyen CM, Cote M, Landcop M-C, Boudreault J-R, Rouleau J, Roy L, Gleeton O, Barbeau G, Noel B, Courtis J, Dagenais GR, Despres J-P, DeLarochelliere R. Comparison of Plaque Sealing With Paclitaxel-Eluting Stents Versus Medical Therapy for the Treatment of Moderate Nonsignificant Saphenous Vein Graft Lesions: The Moderate VEin Graft LEsion Stenting With the Taxus Stent and Intravascular Ultrasound (VELETI) Pilot Trial. Circulation. 2009;120:1978-1986.
32. Jensen LO, Maeng M, Mintz GS, Christiansen EH, Hansen KN, Galloe A, Kelbaek H, Lassen JF, Thuesen L, Thayssen P. Serial intravascular ultrasound analysis of peri-stent remodeling and proximal and distal edge effects after sirolimus-eluting or paclitaxel-eluting stent implantation in patients with diabetes mellitus. Am J Cardiol. 2009;103:1083-1088.
33. Oikawa Y, Yajima J, Costa MA, Matsuno S, Akabane M, Funada R, Inaba T, Nakagawa Y, Nakamura M, Nagashima K, Kirigaya H, Ogasawara K, Sawada H, Aizawa T. Intravascular ultrasound, angio-scopic and histopathological characterisation of heterogeneous patterns of restenosis after sirolimus-eluting stent implantation: insights into potential "thromborestenosis" phenomenon. EuroIntervention. 2010;6: 380-387.
34. Goldstein JA. Angiographic plaque complexity: the tip of the unstable plaque iceberg. J Am Coll Cardiol. 2002;39:1464-1467. (Pubitemid 34439061)
35. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
36. Rittersma SZH, van der Wal AC, Koch KT, Piek JJ, Henriques JPS, Mulder KJ, Ploegmakers JPHM, Meesterman M, de Winter RJ. Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention. Circulation. 2005;111:1160-1165. (Pubitemid 40365478)
37. Spanos V, Stankovic G, Tobis J, Colombo A. The challenge of in-stent restenosis: insights from intravascular ultrasound. Eur Heart J. 2003;24: 138-150. (Pubitemid 36168469)
38. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, Smits P, McClean D, Verheye S, Belardi J, Condado J, Pieper M, Gambone L, Bressers M, Symons J, Sousa E, Litvack F. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxeleluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol. 2005;46:253-260. (Pubitemid 40966852)
39. Grube E. 12-Month angiographic follow-up of the novel non-polymeric Biolimus A9-coated stent for the treatment of de novo coronary lesions: results from the prospective, multicenter, randomized BIOFREEDOM Clinical Trial. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 21 to 25, 2010; Washington DC.
40. Tanner FC, Yang ZY, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res. 1998;82:396-403. (Pubitemid 28101197)
41. Schomig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1373-1380. (Pubitemid 47449734)
42. Frobert O, Lagerqvist B, Carlsson J, Lindback J, Stenestrand U, James SK. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol. 2009;53:1660-1667.
43. James S. Safety and drug-eluting stents. Paper presented at: European Society of Cardiology Congress; August 28 to September 1, 2010; Stockholm, Sweden.
44. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelba k H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136-146.
45. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujii K, Yasuda T, Costa RA, Moussa I, Dangas GD, Mehran R, Lansky AJ, Kreps E, Collins MB, Colombo A, Stone GW, Leon MB, Moses JW. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation. 2004;110:3430-3434. (Pubitemid 39602221)
46. Biondi-Zoccai G, Moretti C, Abbate A, Sheiban I. Percutaneous coronary intervention for small vessel coronary artery disease. Cardiovasc Revasc Med. 2010;11:189-198.
47. Briguori C, Sarais C, Pagnotta P, Liistro F, Montorfano M, Chieffo A, Sgura F, Corvaja N, Albiero R, Stankovic G, Toutoutzas C, Bonizzoni E, Di Mario C, Colombo A. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol. 2002;40:403-409. (Pubitemid 34833152)
48. Eshtehardi P, Cook S, Wandel S, Raber L, Wenaweser P, Togni M, Vogel R, Garachemani A, Eberli FR, Luscher TF, Juni P, Hess OM, Meier B, Windecker S. Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study. EuroIntervention. 2010;6:467-474.
49. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation. 1998;98:1875-1880. (Pubitemid 28509283)
50. Brodie BR, Stuckey T, Downey W, Humphrey A, Bradshaw B, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Smith H, Edmunds J, Varanasi J, Simonton CA, STENT Group. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) Group. J Am Coll Cardiol Intv. 2008;1:405-414.
51. Pieter Kappetein. Optimal revascularization strategy in patients with three-vessel disease and/or left main disease. The 3-year Outcomes of the SYNTAX Trial. Paper presented at: 24th EACTS Annual Meeting; September 11 to 15, 2010; Geneva, Switzerland.
52. Otsuka Y, Chronos NA, Apkarian RP, Robinson KA. Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher stents. J Invasive Cardiol. 2007;19:71-76.
53. Basalus MW, Ankone MJ, van Houwelingen GK, de Man FH, von Birgelen C. Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. EuroIntervention. 2009;5:157-165.
54. Wiemer M, Butz T, Schmidt W, Schmitz KP, Horstkotte D, Langer C. Scanning electron microscopic analysis of different drug eluting stents after failed implantation: from nearly undamaged to major damaged polymers. Catheter Cardiovasc Interv. 2010;75:905-911.
55. Guerin P, Pilet P, Finet G, Goueffic Y, N'Guyen JM, Crochet D, Tijou I, Pacaud P, Loirand G. Drug-eluting stents in bifurcations: bench study of strut deformation and coating lesions. Circ Cardiovasc Interv. 2010;3: 120-126.
56. Canan T, Lee MS. Drug-eluting stent fracture: incidence, contributing factors, and clinical implications. Catheter Cardiovasc Interv. 2010;75: 237-245.
57. Kim HS, Kim YH, Lee SW, Park DW, Lee CW, Hong MK, Park SW, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ. Incidence and predictors of drug-eluting stent fractures in long coronary disease. Int J Cardiol. 2009;133:354-358.
58. de Ribamar Costa J Jr, Mintz GS, Carlier SG, Fujii K, Sano K, Kimura M, Tanaka K, Costa RA, Lui J, Na Y, Castellanos C, Biro S, Moussa I, Stone GW, Moses JW, Leon MB. Intravascular ultrasound assessment of drug-eluting stent expansion. Am Heart J. 2007;153:297-303. (Pubitemid 46096874)
59. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, Moussa I, Dangas G, Mehran R, Lansky AJ, Reyes A, Kreps E, Collins M, Colombo A, Stone GW, Teirstein PS, Leon MB, Moses JW. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation. 2004;109:1085-1088. (Pubitemid 38332610)
60. Casella G, Klauss V, Ottani F, Siebert U, Sangiorgio P, Bracchetti D. Impact of intravascular ultrasound-guided stenting on long-term clinical outcome: a meta-analysis of available studies comparing intravascular ultrasound-guided and angiographically guided stenting. Catheter Cardiovasc Interv. 2003;59:314-321. (Pubitemid 36792388)
61. Jakabcin J, Spacek R, Bystron M, Kvasnak M, Jager J, Veselka J, Kala P, Cervinka P. Long-term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS guidance. Randomized control trial. HOME DES IVUS. Catheter Cardiovasc Interv. 2010;75:578-583.
62. Colombo A. AVIO: a prospective randomized trial of intravascular- ultrasound guided compared to angiography guided stent implantation in complex coronary lesions. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 21 to 25, 2010; Washington, DC.
63. Honda Y, Fitzgerald PJ. Stent expansion as a mechanical parameter to predict late stent patency: back to the basics. J Am Coll Cardiol Cardiovasc Interv. 2009;2:1276-1278.
64. Costa MA, Angiolillo DJ, Tannenbaum M, Driesman M, Chu A, Patterson J, Kuehl W, Battaglia J, Dabbons S, Shamoon F, Flieshman B, Niederman A, Bass TA. Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). Am J Cardiol. 2008; 101:1704-1711.
65. Liu X, Tsujita K, Maehara A, Mintz GS, Weisz G, Dangas GD, Lansky AJ, Kreps EM, Rabbani LE, Collins M, Stone GW, Moses JW, Mehran R, Leon MB. Intravascular ultrasound assessment of the incidence and predictors of edge dissections after drug-eluting stent implantation. J Am Coll Cardiol Cardiovasc Interv. 2009;2:997-1004.
66. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation. 2005;111:1619-1626. (Pubitemid 40525161)
67. Piscione F, Piccolo R, Cassese S, Galasso G, De Rosa R, D'Andrea C, Chiariello M. Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison. EuroIntervention. 2010;5:853-860.
68. Patrick W Serruys, Gregg W Stone. Comparison of everolimus vs pac-litaxel stents: the SPIRIT program. Paper presented at: American Heart Association Scientific Sessions; November 13 to 17 2010; Chicago, IL.